Evidence map›Paper›PMID 39971809›Full record

ArticleEJNMMI research2025

Diagnostic and prognostic role of

Ritai Na, Zhao Chen, Yongshun Liu, Qianrui Chen, Qi Yang, Yongkang Qiu, Tianyao Wang, Lele Song, Sitong Wu, Wenpeng Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ritai Na *Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Zhao Chen *Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Yongshun LiuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Qianrui ChenDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Qi YangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Yongkang QiuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Tianyao WangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Lele SongDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Sitong WuDepartment of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China.
Wenpeng HuangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Xinyao SunDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China.
Shaozhong XianDepartment of Urology, Beijing Luhe Hospital, Capital Medical University, No. 82 Xinhua South Str., Tongzhou District, Beijing, China. hsn820628@163.com.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng District, Beijing, China. kanglei@bjmu.edu.cn.ORCID http://orcid.org/0000-0001-8729-4547

Funding

Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park Z221100007422027Beijing Science Foundation for Distinguished Young Scholars JQ21025National High Level Hospital Clinical Research Funding 2023IR17National High Level Hospital Clinical Research Funding 2024IR07National Natural Science Foundation of China 82171970Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital 2024CX20
6 · The paper itself

Abstract

backgroundSarcomatoid differentiation is an invasive dedifferentiated feature of tumor and associated with poor prognosis in renal cell carcinoma (RCC) patients. This study aimed to evaluate the utility of

resultsThis retrospective study assessed newly diagnosed sarcomatoid differentiation renal cell carcinoma (SDRCC) patients who were staged using

conclusions

Indexed as

DiagnosisPET/CTPrognosisRenal cell carcinomaSarcomatoid differentiation

Identifiers

PMID39971809
PMCPMC11839549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.